Abstract: A pharmaceutical formulation in the form of agglomerates comprising a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 1-15% by weight of water-insoluble, film-forming polymers, d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients, the sum of the components a) to e) being 100% by weight.

Abstract: A pharmaceutical formulation in the form of agglomerates comprising a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 1-15% by weight of water-insoluble, film-forming polymers, d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients, the sum of the components a) to e) being 100% by weight.

Abstract: A solid oral pharmaceutical dosage form of a sympathomimetic with impeded extractability of the sympathomimetic, comprising I) a sympathomimetic (component I) II) an excipient mixture (component II) composed of a) 5 to 50% by weight of hydroxyalkylcelluloses or alkylcelluloses or mixtures thereof b) 5 to 70% by weight of xanthan c) 5 to 50% by weight of an alkaline earth metal salt of a C10-C30 fatty acid d) 10 to 70% by weight of an alkali metal or alkaline earth metal salt of a mineral acid, of a sulfonic acid or of a C2-C6 carboxylic acid or mixtures thereof, where the total of components a) to d) is 100% by weight, where the ratio of active ingredient to excipient mixture II) is from 1:2 to 3:1 by weight.